The news: On April 30, 2026, the FDA proposed removing the GLP-1 drugs semaglutide, tirzepatide and liraglutide from the 503B bulks list, saying there is “no current clinical need” for outsourcing facilities to compound them from bulk substances. If finalised, it would effectively end large-scale compounding of these blockbuster weight-loss and diabetes drugs. A public comment period runs to the end of June 2026. Note: this concerns human-use prescription compounding — a separate world from research-use-only compounds.
This article summarises and comments on reporting by Medical News Today: “FDA proposes ban on bulk compounding of semaglutide, tirzepatide” (May 10, 2026). Read the original for the full report.
The compounded-GLP-1 era looks to be ending. After two years in which compounding pharmacies filled a gap created by nationwide shortages of Ozempic, Wegovy, Mounjaro and Zepbound, the FDA has signalled that the large-scale version of that practice has no long-term regulatory future. Here is what the proposal actually says — and, just as importantly, what it does not touch.
According to Medical News Today’s report, on April 30, 2026 the FDA announced it is considering removing semaglutide (the molecule in Ozempic and Wegovy), tirzepatide (Mounjaro and Zepbound) and liraglutide (Victoza and Saxenda) from the 503B bulks list. The agency’s stated rationale is that there is “no current clinical need” for outsourcing facilities to compound these drugs from bulk active ingredient now that the branded products are widely available again.
Compounding in the US runs on two tracks. 503B outsourcing facilities make larger batches of compounded medicine for general distribution to clinics and hospitals. 503A pharmacies prepare medications for an individual patient against a specific prescription. The April 2026 proposal targets the 503B bulks pathway — the mass-production route. Commentators note the proposal appears to leave a narrower door open for certain patient-specific 503A formulations, though the overall direction of travel is clear.
Why now? The compounding boom was driven by official shortages — the FDA declared the semaglutide and tirzepatide shortages resolved across 2024–2025. Once a drug is no longer in shortage, the legal justification for compounding copies of it narrows sharply. Medical News Today also notes research linking compounded GLP-1s to a greater risk of adverse events, an additional safety argument the agency has leaned on.
This is a proposal, not yet a final rule. A public comment period runs until the end of June 2026, after which the FDA weighs the feedback before finalising. As with all rulemaking, the practical timeline to a binding outcome can stretch well beyond the comment deadline.
It is worth being precise here, because the headlines blur it: this news is about licensed pharmacies and outsourcing facilities compounding human-use prescription medicines. That is a separate legal and practical world from research-use-only compounds, which are supplied to laboratories as reagents, labelled research use only and not for human consumption. The 503B bulks proposal does not address the research-compound space, and nothing about it changes the research-use-only framing that responsible suppliers operate under.
If you want the broader regulatory map, our Are peptides legal? guide and our FDA peptide approval pipeline piece set out how approval, compounding and research use differ.
What did the FDA propose for compounded GLP-1s?
To remove semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026), citing no current clinical need; comments close end of June 2026.
What is 503B vs 503A?
503B = bulk batches from outsourcing facilities; 503A = patient-specific prescriptions. The proposal targets the 503B bulks route.
Does this affect research-use-only compounds?
No. It governs human-use prescription compounding, a separate category from research-use-only material that is not for human consumption.
Primary source: Medical News Today, “FDA proposes ban on bulk compounding of semaglutide, tirzepatide” (May 10, 2026). External links are provided for research reference only; New-U is not affiliated with these organisations and links carry no endorsement either way.
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
Browse the catalogAt New-U, we believe better conversations start with better information. For laboratory research use only. Not for human consumption.